ENTvantage Diagnostics Inc.
Point-of-care diagnostic for sinusitis avoids antibiotic overuse
This article was originally published in Start Up
Sinusitis is one malady that is prone to antibiotic overuse - antibiotics are prescribed for some 50% of patients, partly because busy physicians don’t feel they have the time to explain to them why an antibiotic is not appropriate. ENTvantage Diagnostics Inc. is developing a point-of-care diagnostic to quickly determine whether patients have bacterial or viral sinusitis.
You may also be interested in...
For innovators in the medical device industry, the otolaryngology or ENT (ear, nose, and throat) specialty offers just about everything that investors look for these days. Profiles of Aerin Medical, Spirox, Fiagon AG Medical, and ENTvantage Diagnostics.
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.